BlackBerry Ltd

BlackBerry Ltd (NYSE: BB) is the leading provider of security software to enterprises and the government.

Investment Rationale – WATCH at USD 9.88

• With regards to the top-line business, the Company had posted approximately 15.53% year-on-year drop in revenue during Q1 FY22.
• The stock price is highly volatile as it witnessed a drop of around 65.66% from the levels of 52 -week high of USD 28.77 reached on 27 January 2021.
• The consensus forecast had indicated that the Company would remain loss-making for FY22 and FY23.
• From a technical standpoint, BB is trading lower than the 20-days exponential moving average of USD 11.48, indicating a correction in the stock price.

One Year Share Price Chart

 (Data Source: Refinitiv, Analysis by Kalkine Group)

Conclusion

Based on the volatile nature of the stock and a drop in top-line revenue during Q1 FY22, we have given a “WATCH” recommendation on BlackBerry Ltd at the closing market price of USD 9.88 (as of 19 July 2021).

Sundial Growers Inc

Sundial Growers Inc (Nasdaq: SNDL) is a consumer-packaged goods entity that operates through two segments – Cannabis and Investment.

Investment Highlights – WATCH at USD 0.8086

• In the last financial update for Q1 FY21 (for the three months ended 31 March 2021):
  • SNDL reported a decline in revenue and worsened net losses versus Q1 FY20.
  • Revenue and Net Income from continuing operations were declined by 29% and 255%, respectively, against Q1 FY20.
• Due to Covid-19 uncertainties, SNDL might fail to achieve expected sales volume, and there is a likelihood of higher contingent liabilities.
• From a technical standpoint, the current market price is sustaining below the 20-day EMA (USD 0.89), reflecting a bearish price momentum.
• In the last year, SNDL' s price has fallen ~60.99%, reflecting significant underperformance against the Nasdaq index benchmark.
• On & July 2021, SNDL raised commitment to SunStream Bancorp by CA$350 million.

Share Price Chart

 (Data Source: REFINITIV, Analysis done by Kalkine Group)

Conclusion

Based on the weak fundamentals, the substantial downtrend in prices, unfavourable technical stance, and macroeconomic uncertainty, we have given an “WATCH” stance on Sundial Growers Inc at the closing price of USD 0.8086 (as on 19 July 2021), while we look forward to reviewing the FY21 results.  

Corbus Pharmaceuticals Holdings Inc

Corbus Pharmaceuticals Holdings Inc (Nasdaq: CRBP) is a clinical-stage drug development entity focusing on the endocannabinoid system.

Investment Rationale – WATCH at USD 1.42

• In terms of financials for Q1 FY21
  • CRBP did not generate any product revenue, and even the revenue from ‘award and licenses’ reduced significantly against Q1 FY20.
  • At the end of Q1 FY21, the Company had US$125 million in cash and cash equivalents.
• As of 31 March 2021, CRBP had approximately US$320,159,000 in accumulated deficit.
• CRBP reported top-line results from DETERMINE Phase 3 Study of Lenabasum on 24 June 2021.
• The growth trajectory depends upon external financial resources since the Company has negative cash flows from operations.
• From a technical standpoint, the current market price is sustaining below the 20-day EMA (USD 1.71), reflecting a bearish price momentum.
• In the last one year, CRBP’s s price has fallen ~79.45%, reflecting significant underperformance against the benchmark, Nasdaq index.

Share Price Chart

 (Data Source: REFINITIV, Analysis done by Kalkine Group)

Conclusion

Based on the reduced revenue generation, negative cash flows from operations, significant losses, bearish price momentum, and macroeconomic uncertainties, we have given an “WATCH” stance on Corbus Pharmaceuticals Holdings Inc at the closing price of USD 1.42 (as on 19 July 2021), while we look forward to monitoring how the Covid-19 pandemic will impact its business and operations.

Palatin Technologies Inc

Palatin Technologies Inc (AMEX: PTN) is a biopharmaceutical entity focusing on melanocortin and natriuretic peptide receptor systems.

Investment Rationale – WATCH at USD 0.5111

• On 17 June 2021, the Company reported Q3 FY21 results and reported
  • US$68.6 Million in Cash and Cash Equivalents as of 31 March 2021.
  • 89% increase in gross products sales and 154% increase in net revenue against Q1 FY20.
  • However, net loss was aggravated against Q1 FY20 due to higher operating expenses.
• On 29 June 2021, PTN reported Positive End-of-Phase 2 Meeting with FDA on PL9643 regarding the treatment of dry eye disease.
• As of 31 March 2021, PTN had accumulated deficit of US$337,861,113. Moreover, the profitability is uncertain in the foreseeable future.
• From a technical standpoint, the current market price is sustaining below the 20-day EMA (USD 0.57), reflecting a bearish price momentum.
• In the past six months, PTN’ s price has fallen ~43.21%, reflecting significant underperformance against the benchmark, NYSE AMS index.

Share Price Chart

 (Data Source: REFINITIV, Analysis done by Kalkine Group)

Conclusion

Based on the uncertain outlook, history of losses, challenging market conditions, we have given a “WATCH” stance on Palatin Technologies Inc at the closing price of USD 0.5111 (as on 19 July 2021).

Blue Apron Holdings Inc

Launched in 2012, Blue Apron Holdings Inc (NYSE: APRN) provides cooking recipes to its customers.

Investment Rationale – WATCH at USD 4.00

• In Q1 FY21, APRN reported higher operating expenses against Q1 FY20, while it remained into net losses.
• The Company has a history of net losses and negative operating cash flows.
• The Covid-19 pandemic and worsened economic conditions can change the consumer behaviour and their spending habits.
• As of 31 March 2021, APRN had accumulated deficit of US$593,854, against US$578,133 on 31 December 2020.
• From a technical standpoint, the current market price is sustaining below the 20-day EMA (USD 4.19), reflecting a bearish price momentum.
• In the past year, APRN’s s price has fallen ~71.69%, reflecting significant underperformance against the benchmark, NYSE index.

Share Price Chart

 (Data Source: REFINITIV, Analysis done by Kalkine Group)

Conclusion

Based on the uncertain outlook, history of losses, challenging market conditions, we have given a “WATCH” stance on Blue Apron Holdings Inc at the closing price of USD 4.00 (as on 19 July 2021), while we look forward to reviewing its Q2 FY21 results, scheduled for release on 3 August 2021.

Idera Pharmaceuticals Inc

Idera Pharmaceuticals Inc (Nasdaq: IDRA) is a clinical-stage biotechnology entity focusing on immuno-oncology therapies.

Investment Rationale – WATCH at USD 1.03

• In Q1 FY21, the Company did not generate any revenue. As of 31 March 2021, the Company had an accumulated deficit of US$717.8 million.
• On 18 May 2021, IDRA announced that it did not meet its primary endpoint of objective response rate and will not continue ILLUMINATE-301.
• From a technical standpoint, the current market price is sustaining below the 20-day EMA (USD 1.14), reflecting a bearish price momentum.
• In the past year, IDRA’s price has fallen ~60.99%, reflecting significant underperformance against the benchmark, Nasdaq index.

Share Price Chart

 (Data Source: REFINITIV, Analysis done by Kalkine Group)

Conclusion

Based on the disappointing objective response rate results from ILLUMINATE-301 uncertain outlook, substantial operating losses, we have given a “WATCH” stance on Idera Pharmaceuticals Inc at the closing price of USD 1.03 (as on 19 July 2021), while we look forward to reviewing how the Company will secure new commercial-stage assets.

*The reference data in this report has been partly sourced from REFINITIV.

Disclaimer - This report has been issued by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and prepared by Kalkine and its related bodies corporate authorised to provide general financial product advice. Kalkine.com.au and associated pages are published by Kalkine.

Any advice provided in this report is general advice only and does not take into account your objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Statement or other offer document for the securities or other financial products referred to in Kalkine reports. You should obtain a copy of the relevant Product Disclosure Statement, Information Statement or offer document and consider the statement or document before making any decision about whether to acquire the security or product.

You should also seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice in this report or on the Kalkine website. Not all investments are appropriate for all people.

The information in this report and on the Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of information contained in its reports, newsletters and websites. All information represents our views at the date of publication and may change without notice.

Kalkine does not guarantee the performance of, or returns on, any investment. To the extent permitted by law, Kalkine excludes all liability for any loss or damage arising from the use of this report, the Kalkine website and any information published on the Kalkine website (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine hereby limits its liability, to the extent permitted by law, to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

On the date of publishing this report (referred to on the Kalkine website), employees and/or associates of Kalkine do not hold interests in any of the securities or other financial products covered on the Kalkine website.